|
|
This is only a preview of the paper
Click here to register and get the full text.
Existing members click here to login
|
|
|
Questions to consider: Biopure Corp. ... Biopure prepared two “blood substitutes”, Hemopure and Oxyglobin, for human market and veterinary market. ... The management team of Biopure was split to two sides, releasing the commercial immediately and waiting for the good time. ...
Based on the related Biopure material we have, we recommend that Biopure should not immediately launch the Commercial release of Oxyglobin because the risks of immediate release outweigh the benefits. ... Once the image of low price established, there is no way to get rid of it unless Biopure changes formula which is prohibitive by FDA. ...
(2) Biopure has not to move hesitantly compared with the other competitors (Please see the appendix 1)
Supporting evidence 1: Sony vs. ...
Supporting evidence 2: Release date (Biopure’s is earlier than other’s)
Although Biopure postpones the release of Oxglobin, it can be the first comer in both human and animal market after two years. ... Although Baxter can reduce commercial product right now, it cannot receive its FDA approval earlier than Biopure. Furthermore, Northfiled has no enough manufacturing ability (only 10,000 units per year) even it can obtain its FDA approval in the same time as Biopure. ...
Biopure’s manufacturing cost is higher than Baxster’s (as shown in appendix 2) because of its higher comparatively fixed cost. ... Even if Biopure increase its capacity 5 times, from 100,000 to 500,000, the fixed cost will increase only 2 times or less.
Approximate Word count = 1109
Approximate Pages = 4.4
(250 words per page double spaced)
|
|
|
|
|
|